UTMB Clinical and Translational Science Award

德克萨斯大学医学分支（UTMB）的CTSA位于翻译研究所内， 科学（ITS），三个独立的UTMB机构之一，成立于2007年。在其作为家庭的作用， 临床和转化研究，ITS提供主要的终身教职任命7早， 职业翻译科学家在过去的5年半里，我们改变了UTMB的研究文化， 从一个只重视个人实验室研究的机构， 多学科翻译团队（MTT）的方法来解决重大的健康问题。我们有 开发了新颖的教育课程，在特殊人群中开展了重要的临床研究项目， 研究中心临床试验（CT），并在德克萨斯州地区CTSA联盟（TRCC）中担任领导职务， 全国范围内。UTMB CTSA中心的使命是通过以下方式支持国家的健康目标： 生成、测试和传播综合团队科学、教育和最佳实践， 各阶段的利益相关者参与。通过使用创新的持续改进模型进行管理 记分卡，UTMB CTSA将解决四个具体目标，以：1）培训多样化的劳动力在真实的 推进翻译研究各个阶段所需的技能。我们将团队环境作为 教育框架，以支持不同的学习社区的培训。我们的创新， 企业家精神和团队领导课程将被用来灌输重点，职业阶段适当 在我们的学员中。我们在分享和传播创新教育内容方面处于领先地位， 企业家精神和团队科学。2）。让利益相关者参与所有阶段 翻译研究和CT的重要性。我们将扩大与利益相关者的双向互动 来自社区、患者倡导团体、医疗保健提供者和我们的卫生系统， 需要，确定CTSA的优先事项和传播能力。3）。通过所有类型整合质量体系 转化研究，包括特殊人群的CT。我们领导了一个 通过临床研究办公室为高质量CT提供可持续支持的全校计划， 由经验丰富的主任、可互操作的临床试验管理系统和工作人员提供支持， 简化对CT启动、质量保证监测、研究管理和GCP所有阶段的支持 训练4）。通过基于MTT的创新推进转化研究的开展。UTMB CTSA枢纽是唯一的在其系统应用的混合产业，学术MTT的国家财团 模型，并建立了一个证据基础，说明了 成功的MT我们将通过促进团队发展，领导力发展， 通过独特的领导力发展学院，并将治疗和设备推进到I/II期 我们的“分子治疗和设备创新”可选模块中的CT。

The CTSA at the University of Texas Medical Branch (UTMB) is located within the Institute for Translational Science (ITS), one of three free-standing UTMB institutes, established in 2007. In its role as the home for clinical and translational research, the ITS provides primary tenure-earning faculty appointments to 7 early- career translational scientists. Over the past 5½ years, we have transformed UTMB's research culture, growing from an institution that solely valued individual laboratory-oriented research to one that embraces multidisciplinary translational team (MTT) approaches to addressing significant health problems. We have developed novel educational curricula, significant clinical research programs in special populations with multi- site clinical trials (CTs), and provided leadership in the Texas Regional CTSA consortium (TRCC) and nationally. The mission of the UTMB CTSA hub is to support the health goals of the nation by generating, testing and disseminating integrative team science, education and best practices through stakeholder involvement at all stages. Managed by a continuous improvement model using an Innovation Scorecard, the UTMB CTSA will address four specific aims, to: 1) Train a diverse workforce in the authentic skills needed to advance all phases of translational research. We have used the team environment as an educational framework to support the training of diverse learning communities. Our innovation, entrepreneurship, and team leadership curricula will be used to instill focused, career stage-appropriate competencies in our trainees. We have led in sharing and disseminating innovative educational content in entrepreneurship and team science throughout the consortium. 2). Engage stakeholders across all phases of translational research and CTs. We will extend our substantial bidirectional interactions with stakeholders from the community, patient advocacy groups, healthcare providers and our Health System to assess health needs, set CTSA priorities and disseminate competencies. 3). Integrate quality systems through all types of translational research, including CTs in special populations. We have provided leadership to a university-wide plan for sustainable support for high-quality CTs through the Office of Clinical Research, supported by an experienced director, an interoperable Clinical Trial Management System and staff to provide streamlined support for all phases of CT start-up, quality assurance monitoring, study management and GCP training. 4). Advance the conduct of translational research through MTT-based innovation. The UTMB CTSA hub is unique in the national consortium in its systematic application of a hybrid industry-academic MTT model, and have developed an evidence base on the formation, evaluation, impact and trajectories of successful MTTs. We will stimulate MTT innovation by promoting team development, leadership development by a unique Leadership Development Academy, and advancement of therapeutics and devices into Phase I/II CTs in our “Innovations in Molecular Therapeutics and Devices” Optional Module.